Probiotics: Overview of microbiological and immunological characteristics

Expert Review of Anti-Infective Therapy

Volumn 6, Issue 4, 2008, Pages 497-508

  Blandino, Giovanna ^a   Fazio, Davide ^a   Di Marco, Roberto ^b,c  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

^c IRCCS NEUROMED   (Italy)

Author keywords

Guidelines; Health; Microbe and host interaction; Pharmacokinetics; Probiotic bacteria; Taxonomy

Indexed keywords

ANTIBIOTIC AGENT; BIFIDOBACTERIUM ACIDOPHILUS GG EXTRACT; BIFIDOBACTERIUM LACTIS EXTRACT; LACTOBACILLUS ACIDOPHILUS EXTRACT; LACTOBACILLUS CASEI EXTRACT; LACTOBACILLUS CRISPATUS CTV 05 EXTRACT; LACTOBACILLUS FERMENTUM RC 14 EXTRACT; LACTOBACILLUS JENSENII EXTRACT; LACTOBACILLUS JOHNSONII LA1 EXTRACT; LACTOBACILLUS REUTERI EXTRACT; LACTOBACILLUS RHAMNOSUS GG EXTRACT; LACTOBACILLUS RHAMNOSUS GR 1 EXTRACT; NATURAL PRODUCT; PREBIOTIC AGENT; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTINEOPLASTIC ACTIVITY; BACTERIAL STRAIN; BIFIDOBACTERIUM; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG METABOLISM; DRUG POTENTIATION; ENTERITIS; GASTRITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL REFLUX; HELICOBACTER PYLORI; HUMAN; LACTIC ACID BACTERIUM; LACTOBACILLUS; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; NONHUMAN; REVIEW; UROGENITAL TRACT INFECTION; VAGINA CANDIDIASIS; ARTICLE; HEALTH PROMOTION; PHYSIOLOGY;

BIFIDOBACTERIUM; GASTROINTESTINAL DISEASES; HEALTH PROMOTION; HUMANS; LACTOBACILLUS; PROBIOTICS;

EID: 54449085909     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.6.4.497     Document Type: Review

References (100)

1. Metchnikoff E. Lactic acid as inhibiting intestinal putrefaction. In: The Prolongation of Life Optimistic Studies. Heinemman W (Ed.). London, UK 161-183 (1907).
2. Lilly DM, Stillwell RM. Probiotics: growth promoting factors produced by microorganisms. Science 147, 747-748 (1965).
3. Füller R. Probiotics in man and animals. J. Appl. Bacteriol. 66, 365-378 (1989).
4. Guarner F, Schaafsma GJ. Probiotics. Int. J. Food Microbiol. 39, 237-238 (1998).
5. Joint FAO/WHO Expert Consultation. Health and Nutritional properties of probiodcs in food including powder milk with live lactic acid bacteria. Joint FAO/WHO Expert Consultation, Cordoba, Argentina, 1-4 October 2001.
6. Guidelines for the evaluation of probiotics in food: Joint FAO/WHO Working Group meeting, London, UK, ON, Canada, 30 April-1 May, 2002.
7. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 361, 512-519 (2003).
8. Saarela M, Mogensen G, Fondén R, Mättö J, Mattila-Sandholm T. Probiotic bacteria: safety, functional and technological properties. J. Biotechnology 84, 197-215 (2000).
9. Reid G, Jass J, Sebulsky MT, McCornick JK. Potential uses of probiotics in clinical practice. Clin. Microbiol. Rev. 16(4), 658-672 (2003).
10. Mercenier A, Pavan S, Pot B. Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr. Pharm. Des. 9(2), 175-191 (2003).
11. O'Hara AM, Shanahan F. Mechanisms of action of probiotics in intestinal diseases. Scientific World Journal 7, 31-46 (2007).
12. Del Piano M, Morelli L, Strozzi GP et al. Probiotics: from research to consumer. Dig. Liver. Dis. 38(Suppl.2), S248-S255 (2006).
13. Parvez S, Malik KA, Ah Kang S, Kim HY. Probiotics and their fermented food products are beneficial for health. J. Appl. Microbiol. 100, 1171-1185 (2006).
14. Holzapfel WE, Schillinger U. Introduction to pre- and probiotics. Food Res. Int. 35, 109-116 (2002).
15. Falagas ME, Betsi GI, Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. Clin. Microbiol. Infect. 13, 657-664 (2007).
16. Savage DC, Dubos R, Schaedler RW. The gastrointestinal epithelium and its autochthonous bacterial flora. J. Exp. Med. 127, 67-76 (1968).
17. Bjursell MK, Martens EC, Gordon JI. Functional genomic and metabolic studies of the adaptations of a prominent adult human gut symbiont, Bacteroides thetaiotaomicron, to the suckling period. J. Biol. Chem. 281 (47), 36269-36279 (2006).
18. Rastall RA. Bacteria in the gut: friends and foes and how to alter the balance. J. Nutr. 134, S2022-S2026 (2004).
19. Walter J. The microecology of lactobacilli in the gastrointestinal tract. In: Probiotics and Prebiotics Scientific Aspects. Tannock GW (Ed.). Caister Academic Press, London, UK 51-82 (2005).
20. Brook I. Bacterial interference. Crit. Rev. Microbiol. 25, 155-172 (1999).
21. Zoetendal EG, Collier CT, Koike S, Mackie RI, Gaskins HR. Molecular ecological analysis of the gastrointestinal microbiota: a review. J. Nutr. 134, 465-472 (2004).
22. Haller D. Molecular interactions of commensal enteric bacteria with the intestinal epithelium and the mucosal immune system: implication for chronic intestinal inflammation. In: Probiotics and Prebiotics Scientific Aspects. Tannock GW (Ed). Caister Academic Press, London, UK 129-154 (2005).
23. Haller D, Jobin C. Interaction between resident luminal bacteria and the host: can a healthy relationship turn sour? J. Pediatr. Gastroenterol. Nutr. 38, 123-136 (2004).
24. Kelly D, Campbell JI, Knig TP et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmatic shuttling of PPAR-γ and ReIA. Nat. Immunol. 5, 104-112 (2004).
25. Holzapfel WH, Haberer P, Snel J, Schillinger U, Huis in't Veld JH. Overview of gut flora and probiotics. Int. J. Food Microbiol. 41, 85-101 (1998).
26. Sanders ME, Guarner F, Mills D et al. Selected topics in probiotics and prebiotics: meeting report for the 2004 International Scientific Association for Probiotics and Prebiotics. Curr. Issues Intest. Microbiol. 6, 55-68 (2005).
27. Calder PC, Krauss-Etschmann S, de Jong EC et al. Early nutrition and immunity - progress and perspectives. Br. J. Nutr. 96, 774-790 (2006).
28. Blümer N, Pfefferle PI, Renz H. Development of mucosal immune function in the intrauterine and early postnatal environment. Curr. Opin. Gastroenterol. 23, 655-660 (2007).
29. Kelly D, Coutts AG. Early nutrition and the development of immune function in the neonate. Proc. Nutr. Soc. 59(2), 177-185 (2000).
30. Garrity GM, Bell JA, Lilburn TG. Taxonomy outline of the prokaryotes. In: Bergey's Manual of Systematic Bacteriology (2nd Edition). Garrety GM (Ed.). Spring Vertag, NY, USA (2004).
31. Dellaglio F, Felis GE. Taxonomy of lactobacilli and bifidobacteria. In: Probiotics and Prebiotics Scientific Aspects. Tannock GW (Ed.). Caister Academic Press, London, UK 2, 25-49 (2005).
32. Bernadeau M, Vernoux JP, Henri-Dubernet S, Guéguen M. The Lactobacillus genus. Int. J. Food Microbiol. DOI: 10.1016/ jijfoodmicro.2007.08.015 (2007) (Epub ahead of print).
33. Yeung PS, Kitts CL, Cano R, Tong PS, Sanders ME. Application of genotypic and phenotypic analysis to commercial probiotic strain identify and relatedness. J. Appl. Microbiol. 97, 1095-1104 (2004).
34. Huys G, Vancanney M, D'Haene K, Vankerckhoven V, Goussens H, Swing J. Accuracy of species identity of commercial bacterial cultures intended for probiotic or nutritional use. Res. Microbiol. 157, 803-810 (2006).
35. Holzapfel WH, Haberer P, Geisen R, Björkroth J, Schillinger U. Taxonomy and important features of probiotic microrganisms in food and nutrition. Am. J. Clin. Nutr. 73(Suppl.), S365-S373 (2001).
36. Morelli L. Probiotics: clinics and/or nutrition. Dig. Liver Dis. 34(Suppl. 2) S8-S11 (2002).
37. Gorbach SL. Probiotics in the third millennium. Dig. Liver Dis. 34(Suppl. 2), S2-S7 (2002).
38. Douglas LC, Sanders ME. Probiotics and prebiotics in dietetics practice. J. Am. Diet. Assoc. 108(3), 510-521 (2008).
39. Marteau P, Shanahan F. Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract. Res. Clin. Gastroenterol. 17, 725-7410 (2003).
40. Rastall RA, Gibson GR, Gill HS et al. Modulation of the microbial ecology of the human colon by probiotics, prebiotics and synbiotics to enhance human health: an overview of enabling science and potential applications. FEMS Microbiol. Ecol. 52, 145-152 (2005).
41. Princivalli MS, Paoletti C, Palmieri L et al. Antagonistic activity of Lactobacillus rhamnosus GG against cell invasion by macrolide- and tetracycline-resistant group A streptococci. Proceedings of the 4th Probiotics and Prebiotics New Food jointly with XXX International Congress on Microbiological Ecology and Disease (SOMED), Rome, Italy 3 (2007).
42. Gill HS. Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Pract. Res. Clin. Gastraenterol. 17, 755-733 (2003).
43. Candela M, Seibold G, Vitali B, Lachenmaier S, Eikmanns BJ, Brigidi P. Real time PCR quantification of bacterial adhesion to Caco-2 cells: competition between bifidobacteria and enteropathogens. Res. Microbiol. 156(8), 887-895 (2005).
44. Ljungh A, Wadstrom T. Lactic and bacteria as probiotics. Curr. Issues Intest. Microbiol. 7(2), 73-89 (2006).
45. Sonnenburg JL, Chen CTL, Gordon JI. Genomic and metabolic studies of the impact on a model gut symbiont and host. PLoS Biol. 4, 2213-2226 (2006).
46. Corthésy B, Gaskins HF, Mercenier A. Cross-talk between probiotic bacteria and the host immune system. J. Nutr. 137(3 Suppl. 2), S781-S790 (2007).
47. Salminen MK, Rautelin H, Tynkkynen S et al. Lactobacillus bacteraemia, species identification, and antimicrobial susceptibility of 95 blood isolates. Clin. Infict. Dis. 42(5), 35-44 (2006).
48. Besselink M, Van Santvoort HC, Buskens E et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomized, doubleblind, placebo controlled trial. Lancet 371, 651-659 (2008).
49. Morelli L, Matto J, Wilcks A, Aarts HJM, Bolton D. EU Project. ACE-ART EU project. Healthgrain NUTRAfoods 4(2/3), (2005).
50. Mathur S, Singh R. Antibiotic resistance in food lactic acid bacteria - a review. Int. J. Food Microbiol. 105, 281-295 (2005).
51. Hummel AS, Hertel C, Holzapfel WH, Franz CM. Antibiotic resistances of starter and probiotic strains of lactic acid bacteria. Appl. Environ. Microbiol. 73, 790-739 (2007).
52. European Commission Opinion of the FEEDAP. Panel on updating of the criteria used in the assessment of bacteria for resistance to antibiotics of human or veterinary importance. EFSA 223, 1-12 (2005).
53. Danielsen M, Wind A. Susceptibility of Lactobacillus spp. to antimicrobial agents. Int. J. Food Microbiol. 82, 1-11 (2003).
54. Temmermann R, Pot B, Huys G, Swings J. Identification and antibiotic susceptibility of bacterial isolates ftom probiotic products. Int. J. Food. Microbiol. 81, 1-10 (2003).
55. Delgado S, Florez AB, Mayo B. Antibiotic susceptibility of Lactobacillus and Bifidobacterium species from human gastrointestinal tract. Curr. Microbiol. 50, 202-207 (2005).
56. Milazzo I, Speciale A. Musumeci R. Fazio D, Blandino G. Identification and antibiotic susceptibility of bacteria isolates from probiotic products available in Italy. New Microbiol. 29, 281-291 (2006).
57. Florez AB, Egervärn M, Danielsen M et al. Susceptibility of Lactobacillus plantarum strains to six antibiotics and definition of new susceptibility resistance cutoff values. Microb. Drug Resist. 12, 252-256 (2006).
58. Ammor MS, Florez AB, Mayo B. Antibiotic resistance in non-enterococcal lactic acid bacteria and bifidobacteria. Food Microbiol. 24, 559-570 (2007).
59. Aquilanti L, Garofalo C, Osimani A, Silvestri G, Vignaroli C, Clementi E Isolation and molecular characterization of antibiotic resistant lactic acid bacteria from poultry and swine meat products. J. Food Prot. 70(3), 557-565 (2007).
60. Blandino G. Antibiotic susceptibility of bacterial isolates from probiotic products available in Italy. Proceedings of the 4th Probiotics and Prebiotics New Food jointly with XXX International Congress on Microbiological Ecology and Disease (SOMED), Rome, Italy I, 3 (2007).
61. D'Aimmo MR, Modesto M, Biavati B. Antibiotic resistance of lactic acid bacteria and Bifidobacterium spp. isolated from dairy and pharmaceutical products. Int. J. Food Microbiol. 115, 35-42 (2007).
62. Flórez AB, Ammor MS, Mayo B, van Hoek AH, Aarts HJ, Huys G. Antimicrobial susceptibility profiles of 32 types strains of Lactobacillus, Bifidobacterium, Lactococcus and Streptococcus spp. Int. J. Antimicrob. Agents 31, 484-486 (2008).
63. Klare I, Konstabel C, Werner G et al. Antimicrobial susceptibilities of Lactobacillus, Pediococcus and Lactococcus human isolates and cultures intended for probiotic or nutritional use. J. Antimicrob. Chemother. 59, 900-912 (2007).
64. Kastner S, Perreten V, Bleuler H, Hugenschmidt G, Lacroix C, Meile L. Antibiotic susceptibility patterns and resistance genes of starter cultures and probiotic bacteria used in food. Syst. Appl. Microbiol. 29(2), 145-155 (2006).
65. Masco L, Van Hoorde K, De Brandt E, Swings J, Huys G. Antimicrobial susceptibility of Bifidobacterium strains from humans, animal and probiotic products. J. Antimicrob. Chemother. 58, 85-94 (2006).
66. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Supplements M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA, USA (2006).
67. Foligne B, Nutten S, Grangette C et al. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J. Gastroenterol. 13(2), 236-243 (2007).
68. Sanders ME, Tompkins T, Heimbach JT, Kolida S. Weight of evidence needed to substantiate a health effect for probiotics and prebiotics. Regulatory considerations in Canada, E.U., and U.S. Eur. J. Nutr. 44, 303-310 (2005).
69. Kaur IP, Chopra K, Saini A. Probiotics: potential pharmaceutical applications. Eur. J. Pharm. Sci. 15, 1-9 (2002).
70. Ouwehand AC, Salminen S, Isolauri E. Probiotics: an overview of beneficial effects. Antonie Van Leeuwenhock 82, 279-289 (2002).
71. Huff BA. Caveat emptor "probiotics" might not be what they seem. Can. Fam. Physician 50, 583-587 (2004).
72. Huys G, Vancanney M, Haene K et al. Accurancy of species identity of commercial bacterial cultures intended for probiotic or nutrional use. Res. Microbiol. 157, 803-810 (2006).
73. Hong HA, Due LM, Cutting SM. The use of bacterial spore formers as probiotics. FEMS Microbiol. Rev. 29, 813-835 (2005).
74. Cagler E, Kargul B, Tanboga I. Bacteriotherapy and probiotics role on oral health. Oral Dis. 11, 131-137 (2005).
75. Meurman JH, Stamatova I. Probiotics: contribution to oral health. Oral Dis. 13, 443-451 (2007).
76. Guarino A, Canani RB, Spagnuolo MI, Albano F, Di Benedetto L. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. J. Pediatr. Gastroenterol. Nutr. 25, 516-519 (1997).
77. Sleator RD, Hill C. Probiotics as therapeutics for the developing world. J. Infect. Developing Countries 1, 7-12 (2007).
78. Casey PG, Gardiner GE, Casey G et al. A five strain probiotic combination reduced pathogen shedding and alleviates disease signs in pigs challenged with Salmonella enterica serovar thyphimurium. Appl. Environ. Microbiol. 73, 1858-1863 (2007).
79. Manzoni P, Mostert M, Leonessa ML et al. Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a randomized study. Clin. Infect. Dis. 42(12), 1735-1742 (2006).
80. Limdi JK, O'Neill C, McLaughlin J. Do probiotics have a therapeutic role in gastroenterology? World J. Gastroenterol. 12(34), 5447-5457 (2006).
81. Johnston BC, Supina AI, Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo- controlled trials. CMAJ 175, 377-383 (2006).
82. Hamilton-Miller JM. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int. J. Antimicrob. Agents 22, 360-366 (2003).
83. Brook I. Microbiology and management of neonatal necrotizing enterodolitis. Am. J. Perinatol. 25(2), 111-118 (2008).
84. Lammers KM, Brigidi P, Vitali B et al. Immunomodulatory effects of probiotic bacteria DNA. IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol. Med. Microbiol. 38, 165-172 (2003).
85. + T lymphocytes mediate colitis in HLA-B27 transgenic rats monoassociated with nonpathogenic Bacteroides vulgatus. Inflamm. Bowel Dis. 13, 317-324 (2007).
86. Peran L, Camuesco, D, Comalada M et al. A comparative study of the preventative effects exerted by three probiotics, Bifidobacterium lactis, Lactobacillus casei and Lactobacillus acidophilus, in the TNBS model of rat colitis. J. Appl. Microbiol. 103, 836-844 (2007).
87. Peran L, Sierra S, Comalada M et al. A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis. Br. J. Nutr. 97, 96-103 (2007).
88. Lorea Baroja M, Kirjavainen PV, Hekmat S, Reid G. Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin. Exp. Immunol. 149, 470-479 (2007).
89. Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm. Bowel Dis. 10, 286-299 (2004).
90. Allez M, Mayer L. Regulatory T cells: peace keepers in the gut. Inflamm. Bowel Dis. 10, 666-676 (2004).
91. Zigra PI, Maipa VE, Alamanos YP. Probiotics and remission of ulcerative colitis: a systematic review. Neth. J. Med. 65, 411-418 (2007).
92. Rakoff-Nahoum S, Medzhiton R. Regulation of spontaneous intestinal tumorogenesis through the adaptor protein MyD 88. Science 317, 124-127 (2007).
93. Parks TP, Xu Q, Lagenaur LA et al. Bacterial therapeutics for the treatment and prevention of urogenital infections. In: Probiotics and Prebiotics Scientific Aspects. Tannock GW (Ed.). Caister Academic Press, London, UK 8, 171-194 (2005).
94. Falagas ME, Betsi GI, Tokas T, Athanasiou S. Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies. Drugs 66(9), 1253-1261 (2006).
95. Reid G, Charbonneau D, Erb J et al. Oral use of Lactobacillus rhamnosus GR-1 and L.fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol. Med. Microbiol. 35, 131-134 (2003).
96. Falagas ME, Betsi GI, Athanasiou. S. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. J. Antimicrob. Chemother. 58(2), 266-272 (2006).
97. Betsi GI, Papadavid E, Falagas ME. Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. Am. J. Clin. Dermatol. 9, 93-103 (2008).
98. Scheneider SM, Griard-Pipau F, Filippi J et al. Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World J. Gastroenterol. 11(39), 6165-6169 (2005).
99. Steidler L. and Neirynck S. Genetically modified probiotics. In: Trobiotics and Prebiotics Scienific Aspects. Tannock GW (Ed.). Caister Academic Press, London, UK 7, 154-170 (2005).
100. Steidler I, Neirynck S, Huyghebaert N et al. Biological containment of generically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat. Biotechnol. 21, 785-789 (2003).